Clinically actionable genetic insights to guide personalized and preventative care

For patients with cancer that need fast answers to support important decisions that inform treatment and for patients with a high-risk of developing cancer looking to accurately stratify risk to inform medical management.

Find clarity in assessing cancer risk

Get the clarity you need to stratify risk for each of your high-risk unaffected patients accurately. Genetic testing helps you determine personalized cancer risk management options based on unique genetic features for each patient you treat – and increases their odds for a healthy future.

The MyRisk® Hereditary Cancer Test with RiskScore® helps you get the clarity you need to determine the best risk management options for your patient in 14 days or less. The multi-gene panel analyzes the risk for 11 cancers to estimate a patient’s 5-year and lifetime risk for developing breast cancer.

Get results in 5-12 days for eligible breast cancer patients with MyRisk STAT

Fast & simple workflow with pre-test & post-test education/admin support

90% of patients have no out-of-pocket cost

Request more information and explore ordering options

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Who is MyRisk for?

Myriad MyRisk Hereditary Cancer Test product

MyRisk is designed for surgeons treating patients diagnosed with or at risk for:

  • Breast cancer*
  • Ovarian cancer
  • Prostate cancer
  • Pancreatic cancer*
  • Uterine cancer
  • Colorectal cancer
  • Skin cancer
  • Gastric cancer
  • Renal cancer
  • Lung cancer
  • Endocrine cancer

Whether you’re a community-based surgeon or part of an acute hospital setting, MyRisk offers the comprehensive genetic insights you need to make informed decisions that can improve patient outcomes and provide peace of mind.

*eligible for MyRisk STAT

“I am very confident in the test results I get from Myriad Genetics. I’ve never questioned them. Myriad has the longest history working with genetic testing. They have the largest database… It’s been my pleasure working with this company.”

Gregory Vidal, MD

Take the next step with MyRisk

Get started by downloading the provider guide to learn more.

Why choose MyRisk?

Lowest

BRCA1/2 VUS rates

With MyRisk, leverage the industry’s lowest BRCA1/2 VUS rates for clarity in treatment decisions.1

Double

Amount of mutations detected

Panel testing can detect nearly double the amount of mutations compared to single gene testing.2

53%

MyRisk helps patients qualify

53% of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10% expected if tested with other labs.3

Testing process made easy

Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.

1. Patient identification

OPTIONS

  • Digital screening with MyGeneHistory
  • Radiology Information Systems
  • Mammography Information Systems

2. Pre-test education
(with board-certified genetic counselor)

INCLUDES

  • Individualized education (on-demand)
  • Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)

3. Ordering

OPTIONS

  • Online portal
  • Virtual/paper orders
  • EMR integrations
  • Phlebotomy support
  • Technical/ordering support

4. Affordability

INCLUDES

  • Personalized cost estimates
  • 9/10 Patients pay $0 ($54 average)
  • Financial assistance and payment plans available

5. Results

INCLUDES

  • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
  • Online portal or results by mail
  • EMR integration
  • Medical management tool included

6. Post-test discussions
(with board-certified genetic counselor)

INCLUDES

  • Individualized discussion of results (on‑demand or scheduled)
  • Detailed summary of notes

Testing process made easy

Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.

1. Patient identification

OPTIONS

  • Digital screening with MyGeneHistory
  • Radiology Information Systems
  • Mammography Information Systems

2. Pre-test education
(with board-certified genetic counselor)

INCLUDES

  • Individualized education (on‑demand)
  • Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)

3. Ordering

OPTIONS

  • Online portal
  • Virtual/paper orders
  • EMR Integrations
  • Phlebotomy support
  • Technical/ordering support

4. Affordability

INCLUDES

  • Personalized cost estimates
  • 9/10 Patients pay $0 ($54 average)
  • Financial assistance and payment plans available

5. Results

INCLUDES

  • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
  • Online portal or results by mail
  • EMR integration
  • Medical Mmnagement tool included

6. Post-test Discussions
(with board-certified genetic counselor)

INCLUDES

  • Individualized discussion of results (on- demand or scheduled)
  • Detailed summary of notes

MyRisk hereditary cancer 48 gene panel

Genes Breast Ovarian Colorectal Uterine Skin Pancreatic Gastric Prostate Renal Lung Endocrine Other
BRCA1
BRCA2
MLH1
MSH2
MSH6
PMS2
EPCAM
CTNNA1
APC
MUTYH Monoallelic
MUTYH Biallelic
CDKN2A (p16INK4a)
CDKN2A (p14ARF)
CDK4
TP53
PTEN
STK11
CDH1
PALB2
ATM
CHEK2
CHEK2 Biallelic
RAD51C
RAD51D
BARD1
BRIP1
BMPR1A
SMAD4
VHL
RET
MEN1
BAP1
TSC1
TSC2
FH
FLCN
TERT
MITF
MET
SDHA
SDHB
SDHC
SDHD
POLD1
POLE
GREM1
AXIN2
NTHL1 Monoallelic
NTHL1 Biallelic
MSH3 Monoallelic
MSH3 Biallelic
HOXB13
EGFR

MyRisk testing provides you with clear results you can trust

Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.

Hear from patients whose lives have been transformed

Play patient testimonial video - Katya Lezin 0

“I’ve had a dozen overnight hospitalizations, the removal of multiple body parts, you know, really trying times emotionally and physically. And it is such a gift to me that I feel like I took one for the team so my kids don’t have to go through that. They get to know what their odds are and they get to do something about it.”

Katya Lezin

Play patient testimonial video - Ashley Dedmon 0

“I felt really empowered because I knew that should something develop they were gonna catch it early. After talking to my doctor again, we explored preventative options that would drastically reduce my risk, even below the average women.”

Ashley Dedmon

Our research studies

SCIENTIFIC PUBLICATIONS

Variant Classification Discordance: A real-world experience of genetic test results in a community-based setting – Presented at San Antonio Breast Cancer Symposium (SABCS), December 2022

SCIENTIFIC PUBLICATIONS

Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows

SCIENTIFIC PUBLICATIONS

Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women

Take the first step towards more informed, personalized cancer care for your patients.

References:
  1. Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
  2. Yorczyk A, et al. Use of panel tests in place of single gene tesets in the cancer genetics clinic. Clin Genet. 2015 Sep;88(3):278-282.
  3. Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.